This is a mechanism module, not a specific disease. Do NOT create a `Rickets` Disease entry: MONDO:0005520 is flagged `MONDO:ambiguous` in MONDO itself, is axiomatized around decreased circulating vitamin D (RO:0004029 HP:0100512) while subsuming the hypophosphatemic branch that is explicitly vitamin D-resistant, and is simultaneously the only human MONDO term available for common nutritional rickets. Disorder entries reference individual nodes via conforms_to (e.g. "defective_skeletal_mineralization#Impaired Hydroxyapatite Deposition at the Mineralization Front").
Conforming nodes substitute the disorder-specific route to mineralization failure: absent 1-alpha-hydroxylation (CYP27B1) or 25-hydroxylation (CYP2R1), vitamin D receptor resistance (VDR), accelerated calcitriol catabolism (CYP3A4), PHEX-FGF23-driven renal phosphate wasting (X-linked hypophosphatemia), tubular phosphate loss (hereditary hypophosphatemic rickets with hypercalciuria, Fanconi syndrome), impaired TNSALP clearance of inorganic pyrophosphate (hypophosphatasia), or the combined phosphate/calcitriol/PTH disturbance of chronic kidney disease.
Scope. This module is deliberately NOT an Xogenesis (pathological structure-formation) module: its terminal output is the FAILURE of a normal mineralization process, not the formation of a pathological material entity, so it carries no OGMS/MPATH anchor stanza. It is also distinct from `osteoporosis_bone_resorption`, which models loss of normally mineralized bone through a resorption/formation imbalance; here bone matrix is produced in normal or increased quantity but is not mineralized. A disorder may conform to both.
Two arms deliberately kept separate. The calciopenic and phosphopenic arms differ diagnostically as well as mechanistically: parathyroid hormone is elevated in the calciopenic arm and normal in the phosphopenic arm, and 25-hydroxyvitamin D is low in nutritional and CYP2R1 disease but normal in the hypophosphatemic rickets. Do not collapse them into one trigger node in a conforming entry.
Does the caspase-9-dependent, phosphate-regulated apoptosis of terminal hypertrophic chondrocytes that produces the rachitic growth plate in mice also operate in human rickets?
HUMAN MODEL MISMATCH
OPEN
human_model_mismatch_caspase9_growth_plate_apoptosis
Attached to:
Growth Plate Hypertrophic Zone Expansion
The cellular mechanism of this node rests on murine genetics: VDR-null, Phex-mutant and diet-induced hypophosphatemic mice, with pharmacological caspase-9 inhibition used to confirm the pathway in vivo. Human evidence for rickets is radiographic and histological rather than mechanistic, and no human study demonstrates the caspase-9 step. The direction of the finding matters for the module because it is what licenses the direct phosphate-to-growth-plate edge that bypasses matrix mineralization; if the human growth plate depended only on the mineralization front, that edge would not be warranted.
Proposed experiments:
Terminal hypertrophic chondrocyte apoptosis in human rachitic growth plate
Is there a quantitative threshold of the local calcium-phosphate product below which mineralization fails, and is it the same across the calciopenic and phosphopenic arms?
KNOWLEDGE GAP
OPEN
knowledge_gap_local_calcium_phosphate_product_threshold
Attached to:
Impaired Hydroxyapatite Deposition at the Mineralization Front
The module asserts that both substrate-deficiency arms converge by lowering the calcium-phosphate product at the mineralization front, but the convergence is stated qualitatively. Neither arm's clinical literature reports a local threshold, and serum measurements are an imperfect proxy for the concentration at the mineralization front. Without it, the module cannot predict which combinations of calcium and phosphate deficit produce rickets.
Calciopenic Substrate Deficiency
trigger
Insufficient calcitriol signalling or insufficient dietary calcium reduces active intestinal calcium absorption. The resulting fall in serum calcium drives secondary hyperparathyroidism, and parathyroid hormone in turn increases renal phosphate excretion, so the calciopenic arm ends in a combined calcium and phosphate deficit at the mineralization front. This single node covers nutritional vitamin D deficiency, dietary calcium deficiency, and the hereditary vitamin D-dependent rickets series, which differ only in where the calcitriol axis is interrupted.
Downstream
-
Impaired Hydroxyapatite Deposition at the Mineralization Front
Reduced calcium and phosphate availability lowers the calcium-phosphate product at the mineralization front below the threshold for hydroxyapatite deposition.
Show evidence (1 reference)
"Vitamin D and calcium deficiencies are common worldwide, causing nutritional rickets and osteomalacia, which have a major impact on health, growth, and development of infants, children, and adolescents"
Establishes vitamin D and calcium deficiency as the calciopenic entry arm producing both rickets and osteomalacia. Evidence source is OTHER because this is an evidence-based consensus document rather than a primary study.
Phosphopenic Substrate Deficiency
trigger
Renal phosphate wasting removes the phosphate substrate directly, without an antecedent fall in serum calcium. In the hereditary hypophosphatemic rickets the wasting is FGF23-driven (PHEX loss of function in X-linked hypophosphatemia, FGF23 gain of function in the autosomal dominant form, DMP1 and ENPP1 loss in the autosomal recessive forms) and is compounded by FGF23 suppression of calcitriol synthesis; in tubular disorders the loss is a direct transport defect. Parathyroid hormone is characteristically normal, which is what distinguishes this arm from the calciopenic one at the bedside.
Used by disorders
Cystinosis
as Electrolyte wasting, rickets, and growth failure
Downstream
-
Impaired Hydroxyapatite Deposition at the Mineralization Front
Hypophosphatemia lowers the calcium-phosphate product at the mineralization front independently of calcium supply.
-
Growth Plate Hypertrophic Zone Expansion
Phosphate additionally acts directly on the growth plate, where it is required for apoptosis of terminal hypertrophic chondrocytes; this arm does not run through matrix mineralization.
Show evidence (2 references)
"This increase in FGF23 impairs activation of vitamin D and attenuates renal phosphate reabsorption, leading to rickets."
States the FGF23-driven route from renal phosphate wasting to rickets that this trigger node represents.
"The latter model demonstrates normal calcium and parathyroid hormone levels, but 1,25-dihydroxyvitamin D levels that are inappropriately low for the degree of hypophosphatemia."
Documents the normal calcium and parathyroid hormone that distinguish the phosphopenic arm from the calciopenic arm, in the Phex-mutant model of X-linked hypophosphatemia.
Mineralization Inhibitor Excess
trigger
Mineralization can fail with an entirely adequate supply of calcium and phosphate if the local inhibitor is not cleared. Tissue-nonspecific alkaline phosphatase hydrolyses extracellular inorganic pyrophosphate, a potent inhibitor of hydroxyapatite crystal growth; when its activity is deficient, pyrophosphate accumulates and blocks mineral deposition. This arm is biochemically the mirror image of the other two, since minerals are excluded from the skeleton and serum calcium may be high rather than low.
Downstream
-
Impaired Hydroxyapatite Deposition at the Mineralization Front
Excess extracellular pyrophosphate blocks hydroxyapatite crystal growth despite adequate mineral substrate.
Show evidence (2 references)
"Among them is inorganic pyrophosphate (PPi), a potent inhibitor of mineralization."
Identifies the accumulating inhibitor that defines this arm. Evidence source is OTHER because this is a review article.
"In hypophosphatasia, extracellular accumulation of TNSALP natural substrates includes inorganic pyrophosphate, an inhibitor of mineralization, which explains the dento-osseous and arthritic complications featuring tooth loss, rickets or osteomalacia, and calcific arthopathies."
Links inhibitor accumulation directly to rickets and osteomalacia, the module's shared output. Evidence source is OTHER because this is a review article.
Impaired Hydroxyapatite Deposition at the Mineralization Front
central effector
The rate-limiting, disorder-agnostic step of the module and its key conformance target. Osteoid is laid down normally, or in excess, but hydroxyapatite is not deposited into it, either because the local calcium-phosphate product is too low or because the pyrophosphate inhibitor is not cleared. Every conforming disorder funnels through this node regardless of which trigger arm it enters by, and it is the step that unifies rickets in the growing skeleton with osteomalacia in the mature one.
Downstream
-
Growth Plate Hypertrophic Zone Expansion
In the growing skeleton the mineralization defect is expressed at the growth plate.
-
Rickets and Osteomalacia
Undermineralized osteoid accumulates throughout the skeleton, producing osteomalacia at any age.
Show evidence (2 references)
"Rickets is seen in association with vitamin D deficiency and in several genetic disorders associated with abnormal mineral ion homeostasis."
States the convergence this node models: unrelated nutritional and genetic lesions produce the same mineralization phenotype.
"Superabundance of extracellular PPi explains the hard tissue complications of HPP that feature premature loss of deciduous teeth and often rickets or osteomalacia as well as calcific arthropathies in some affected adults."
Shows the inhibitor-excess arm reaching the same mineralization endpoint, with the age-dependent split into rickets and osteomalacia. Evidence source is OTHER because this is a review article.
Growth Plate Hypertrophic Zone Expansion
effector
The growth-plate lesion that makes rickets a disease of growing bone. Terminal hypertrophic chondrocytes normally undergo apoptosis before vascular invasion and ossification of the cartilage template. Phosphate is required for that apoptotic step, so when it is deficient the late hypertrophic layer fails to involute and expands, giving the widened, irregular, cupped and frayed metaphysis that defines rickets radiographically. An adult with an identical mineralization defect and closed growth plates develops osteomalacia without this lesion.
Downstream
-
Rickets and Osteomalacia
Expansion and disorganization of the hypertrophic zone is the growth-plate substrate of clinical rickets.
Show evidence (2 references)
"Our studies demonstrate that normal phosphorus levels are required for growth plate maturation and implicate a critical role for phosphate-regulated apoptosis of hypertrophic chondrocytes via activation of the caspase-9-mediated mitochondrial pathway."
Establishes impaired phosphate-dependent hypertrophic chondrocyte apoptosis as the cellular basis of the rachitic growth plate.
"The observation that normalization of mineral ion homeostasis in the VDR-null mice prevents rachitic changes suggests that rickets is secondary to hypocalcemia, hypophosphatemia, or hyperparathyroidism, rather than impaired VDR action."
Shows the growth-plate lesion is downstream of the mineral-ion disturbance itself rather than of any one upstream receptor defect, which is what makes this node shared across the module's trigger arms.
Rickets and Osteomalacia
consequence
The shared clinical output: soft, undermineralized bone presenting as rickets where growth plates are open and as osteomalacia where they are closed, with bone pain, deformity of the weight-bearing long bones, fracture and pseudofracture, growth failure and myopathy. Individual conforming disorders add their own disorder-specific features (alopecia in vitamin D-dependent rickets type 2A, premature deciduous tooth loss in hypophosphatasia, dental abscess in X-linked hypophosphatemia); this node carries only the mineralization phenotype the arms share.
Show evidence (2 references)
"Rickets, osteomalacia, and vitamin D and calcium deficiencies are preventable global public health problems in infants, children, and adolescents."
Records that the module's terminal phenotype is a common global problem in its nutritional form, not a rare-disease endpoint. Evidence source is OTHER because this is an evidence-based consensus document.
"Hypophosphatasia was the last type of rickets or osteomalacia to await a medical treatment."
Treats rickets/osteomalacia as a class of which the individual disorders are types, which is the relationship this module formalizes. Evidence source is OTHER because this is a review article.
Asfotase Alfa Enzyme Replacement
Platform:
Protein replacement
Bone-targeted recombinant tissue-nonspecific alkaline phosphatase. It acts on the inhibitor-excess arm specifically, restoring hydrolysis of extracellular inorganic pyrophosphate so that mineralization can proceed. Included here as the module's worked drug-target pattern; it is arm-specific and is NOT inherited as a treatment recommendation by disorders conforming through the calciopenic or phosphopenic arms, where pyrophosphate is not the problem.